Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

✍ Scribed by Price, Timothy J; Peeters, Marc; Kim, Tae Won; Li, Jin; Cascinu, Stefano; Ruff, Paul; Suresh, Atilli Satya; Thomas, Anne; Tjulandin, Sergei; Zhang, Kathy; Murugappan, Swaminathan; Sidhu, Roger

• Book ID: 121748187
• Publisher: The Lancet
• Year: 2014
• Tongue: English
• Weight: 592 KB
• Volume: 15
• Category: Article
• ISSN: 1470-2045
• DOI: 10.1016/S1470-2045(14)70118-4